TECENTRIQ 
DOSING &
ADMINISTRATION 

TECENTRIQ provides established dosing
options across all indications

Lung

Non-small cell lung cancer (NSCLC)

Indications1
TECENTRIQ, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, TECENTRIQ, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.

 

TECENTRIQ, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.

 

TECENTRIQ as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK+ NSCLC should also have received targeted therapy before receiving TECENTRIQ. 

 

1L Metastatic non-squamous NSCLC

 

TECENTRIQ in combination with bevacizumab, paclitaxel and carboplatin.
A consistent infusion schedule with chemotherapy-free post-induction dosing.

Infusions once every 3 weeks1,2

nsclc1l

1L=first line; AUC=area under the concentration-time curve; IV=intravenous; NSCLC=non-small cell lung cancer.
Based on the dosing schedule from IMpower150.2 Visualization of vials is illustrative and does not represent actual vial usage.
*In patients of Asian race/ethnicity, the paclitaxel dose was lowered from 200 mg/m2 to 175 mg/m2. 

  • TECENTRIQ should be administered prior to bevacizumab, paclitaxel, and carboplatin on Day 1 of each cycle
  • Administer the initial infusion of TECENTRIQ over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes
  • Do not administer TECENTRIQ as an IV push or bolus
  • Do not co-administer other drugs through the same IV line
  • Refer to the respective prescribing information for bevacizumab, paclitaxel, and carboplatin for recommended dosing information

TECENTRIQ in combination with nab-paclitaxel and carboplatin.

Induction phase followed by chemotherapy-free infusions with TECENTRIQ.

 

Infusions once every 3 weeks1,3

nab-carbo

1L=first line; AUC=area under the concentration-time curve; IV=intravenous; nab-pac=nanoparticle albumin–bound paclitaxel; NSCLC=non-small cell lung cancer.

Based on the dosing schedule from IMpower130.3 Visualization of vials is illustrative and does not represent actual vial usage.

  • For each 21-day cycle, TECENTRIQ, nab-pac, and carboplatin are administered on Day 1; in addition, nab-pac is administered on days 8 and 15
  • Administer the initial infusion of TECENTRIQ over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes
  • Do not administer TECENTRIQ as an IV push or bolus
  • Do not co-administer other drugs through the same IV line
  • Refer to the respective prescribing information for the combination products

Review dosage modifications for TECENTRIQ

2L Metastatic NSCLC

TECENTRIQ as monotherapy

 

TECENTRIQ offers flexible dosing options

 

Choose the most suitable infusion schedule for your patients1,4

separate-indications-new-nsclc2l

Q4W dosage is administered with two 840-mg vials of TECENTRIQ.

Visualization of vials is illustrative and does not represent actual vial usage.

2L=second line; IV=intravenous; Q4W=every 4 weeks.

  • Do not administer TECENTRIQ as an IV push or bolus
  • Do not co-administer other drugs through the same IV line

Review dosage modifications for TECENTRIQ

Lung

Small Cell Lung Cancer (SCLC)

Indications1

TECENTRIQ, in combination with carboplatin and etoposide, is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

 

TECENTRIQ, in combination with carboplatin and etoposide

 

TECENTRIQ Infusion Schedule with Chemotherapy-Free Maintenance

 

Q3W combination induction followed by flexible dosing options in maintenance1,5

separate-indications-new-sclc

Dosing information for carboplatin/etoposide is based on IMpower133 trial;

TECENTRIQ was administered Q3W in IMpower133.5 Visualization of vials is illustrative and does not represent actual vial usage.

Q3W=every 3 weeks

  • During induction phase, TECENTRIQ should be administered by IV infusion first, followed by carboplatin, then etoposide
  • During maintenance phase, TECENTRIQ can be administered as 1200 mg every 3 weeks
  • Administer the initial infusion of TECENTRIQ over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes
  • Do not administer TECENTRIQ as an IV push or bolus
  • Do not co-administer other drugs through the same IV line
  • Refer to the respective prescribing information for carboplatin and etoposide for recommended dosing information

Review dosage modifications for TECENTRIQ

Lung

Triple-negative Breast Cancer (TNBC)

Indication4

TECENTRIQ in combination with nab-paclitaxel (nab-pac) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease.

 

TECENTRIQ in combination with nab-paclitaxel.

 

Dosing Schedule Allows Patients an Infusion-Free Week Between Cycles

 

28-day dosing cycles continue until disease progression or unacceptable toxicity4,6

separate-indications-new-tnbc

nab-pac=nanoparticle albumin–bound paclitaxel.

Based on the dosing schedule from IMpassion130.6

Visualization of vials is illustrative and does not represent actual vial usage.

  • For each 28-day cycle, TECENTRIQ is administered on Days 1 and 15, and nab-pac 100 mg/m2  is administered on Days 1, 8, and 15
  • On Days 1 and 15, TECENTRIQ should be administered first, followed by nab-pac
  • Administer the initial infusion of TECENTRIQ over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes
  • Do not administer TECENTRIQ as an IV push or bolus
  • Do not co-administer other drugs through the same IV line
  • TECENTRIQ and nab-pac may be discontinued for toxicity independently of each other
  • See also the prescribing information for nab-pac prior to initiation

840-mg single-dose vial now approved for TECENTRIQ

Review dosage modifications for TECENTRIQ

Lung

Urothelial carcinoma

Indications1,4

TECENTRIQ as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC):

  • After prior platinum containing chemotherapy, or
  • Who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥5%

TECENTRIQ as monotherapy

TECENTRIQ Offers Flexible Dosing Options

 

Choose the most suitable infusion schedule for your patients1,4

separate-indications-new-uc

Based on the dosing schedule from IMvigor2107 and IMvigor20118. Visualization of vials is illustrative and does not represent actual vial usage. 

Q4W dosage is administered with two 840-mg vials of TECENTRIQ.
IV=intravenous; q3w=every 3 weeks.

  • Do not administer as an IV push or bolus
  • Do not co-administer other drugs through the same IV line

Review dosage modifications for TECENTRIQ

Lung

Hepatocellular Carcinoma

UNRESECTABLE HCC

A Cancer Immunotherapy combination schedule once every 3 weeks.1

separate-indications-new-hcc

Based on the dosing schedule from IMbrave1509. Visualization of vials is illustrative and does not represent actual vial usage.

  • TECENTRIQ should be administered first, followed by bevacizumab
  • Administer the initial infusion of TECENTRIQ over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes
  • The recommended dose of TECENTRIQ is 1,200 mg followed by bevacizumab 15 mg/kg of body weight, administered by intravenous infusion every three weeks
  • Do not administer TECENTRIQ as an IV push or bolus
  • Do not co-administer other drugs through the same IV line
  • Refer to the bevacizumab SmPC for prescribing information, dosage modifications or specific adverse reactions

DOSAGE MODIFICATIONS FROM THE TECENTRIQ
PRESCRIBING INFORMATION1†

ADVERSE REACTIONSEVERITY OF ADVERSE REACTION‡DOSAGE MODIFICATIONS
PneumonitisGrade 2Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 3 or 4Permanently discontinue
Hepatitis in patients without hepatocellular carcinoma (HCC)

Grade 2:

(ALT or AST > 3 to 5 x upper limit of normal [ULN]  or blood bilirubin > 1.5 to 3 x ULN)

Withhold Tecentriq  

 

Treatment may be resumed when the event improves to Grade 0 or Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day

Grade 3 or 4:

(ALT or AST > 5 x ULN or blood bilirubin > 3 x ULN)

Permanently discontinue TECENTRIQ
Hepatitis in patients with HCC

If AST/ALT is within normal limits at baseline and increases to >3x to ≤10x ULN or  

 

If AST/ALT is >1 to ≤ 3x ULN at baseline and increases to >5x to ≤ 0x ULN or  

 

If AST/ALT is >3x to ≤ 5x ULN at baseline and increases to >8x to ≤ 10x ULN 

Withhold Tecentriq  

 

Treatment may be resumed when the event improves to Grade 0 or Grade 1 within 12 weeks and corticosteroids have been reduced
to ≤ 10 mg prednisone or equivalent per day

If AST/ALT increases to >10x ULN or  total bilirubin increases to >3x ULNPermanently discontinue Tecentriq
Colitis or diarrhoeaGrade 2 or 3Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4Permanently discontinue
Endocrinopathies§Grade 2, 3, or 4Withhold dose until grade 1 or resolved and clinically stable on hormone replacement therapy
Other immune-mediated adverse reactions involving a major organGrade 3Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4Permanently discontinue
InfectionsGrade 3 or 4
Withhold dose until grade 1 or resolved
Infusion-related reactionsGrade 1 or 2Interrupt or slow the rate of infusion
Grade 3 or 4Permanently discontinue
Persistent grade 2 or 3 adverse reaction (excluding endocrinopathies)Grade 2 or 3 adverse reaction that does not recover to grade 0 or 1 within 12 weeks after last TECENTRIQ dosePermanently discontinue
Inability to taper corticosteroidInability to reduce to less than or equal to prednisone 10 mg per day (or equivalent) within 12 weeks after last TECENTRIQ dosePermanently discontinue
Recurrent grade 3 or 4 adverse reactionRecurrent grade 3 or 4 (severe or life-threatening) adverse reactionPermanently discontinue

ALT=alanine aminotransferase; AR=adverse reaction; AST=aspartate aminotransferase; IV=intravenous; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; ULN=upper limit of normal.

†Consult the nab-pac Prescribing Information for dosage modifications and AR management.

‡NCI CTCAE v4.0.

§Including, but not limited to, hypophysitis, adrenal insufficiency, hyperthyroidism, and type 1 diabetes mellitus.

RESOURCES

Curious to see more resources and download material?

CONNECTING YOU WITH YOUR PATIENTS

At Roche, we believe in a shared purpose in improving the care and treatment of patients living with difficult to treat cancers. We understand and empathise with the demands you face managing the needs of these patients.

Roche is committed to exploring new treatment options to individualise treatment and meet patients’ needs. TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to exploring new combinations to improve patient outcomes (ref. SmPC). 

TECENTRIQ is an anti PD-L1 cancer immunotherapy that specifically targets PD-L1 on tumour and tumour-infiltrating immune cells across a broad range of solid tumours. TECENTRIQ offers a pioneering, targeted treatment with proven efficacy and an acceptable tolerability profile (ref. SmPC). Please see the specific indications for more information.

CONNECTING TECENTRIQ AND COMBINATIONS

TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to explore new combinations for better patient outcomes (ref. SmPC).

In many difficult-to-treat tumour types with a high unmet need, including metastatic urothelial carcinoma, triple negative breast cancer and lung cancer (non-small cell lung cancer and small cell lung cancer), TECENTRIQ has shown significant improvements in progression-free and/or overall survival (ref. SmPC). Importantly, treatment can be tailored (i.e., in combination with the standard of care, or different dosing schedules) according to the type of cancer and the patient’s individual needs (ref. SmPC).
Read SmPC for more details

The multiple indications of TECENTRIQ (ref. SmPC)
provide a wealth of data to inform treatment decision-making and deliver valuable reassurance when considering the needs of your patients with cancer. Please see the specific indications for more information.

CONNECTING PATIENTS TO THEIR LOVED ONES

TECENTRIQ treatment offers the potential to improve treatment outcomes and maintain patient quality of life in your difficult to treat cancer patients, so they can hopefully spend more time with their loved ones.

TECENTRIQ is approved in metastatic urothelial carcinoma, non-small cell lung cancer, extensive-stage small cell lung cancer and triple negative breast cancer (ref. SmPC).

  1. Tecentriq 1,200 mg concentrate for solution for infusion. Summary of Product Characteristics. Updated 10-Jun-2020 | Roche Products Limited. Available from: https://www.medicines.org.uk/ (Accessed September 2022).
  2. Socinski MA, et al; IMpower 150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-301.
  3. West H, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924-37.
  4. Tecentriq 840 mg concentrate for solution for infusion. Summary of Product Characteristics. Updated 2-Sep-2020 | Roche Products Limited. Available from: https://www.medicines.org.uk/ (Accessed September 2020).
  5. Horn L, et al. IMPower 133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-9.
  6. Schmid P, et al; IMpassion 130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-21.
  7. Balar AV, Galsky MD, Rosenberg JE, et al. IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet doi 10.1016/sS0140-6736 (16) 32455-2.
  8. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial [published correction appears in Lancet. 2018;392(10156):1402]. Lancet. 2018;391(10122):748-757.
  9. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-1905.